PPIDT00322
Drug Information
| Name | Ocrelizumab |
|---|---|
| Sequence | RASSSVSYMH |
| DrugBank_ID | DB11988 |
| Type | biotech |
| Indication | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Ocrelizumab is also indicated for the treatment of primary progressive MS in adults.[L42895] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
300 mg/10mL
|
| Injection, solution | Subcutaneous |
920 mg
|
| Injection, solution, concentrate | Intravenous |
300 mg
|
| Injection, solution, concentrate | Intravenous; Parenteral |
300 MG
|
| Solution | Intravenous |
30 mg / mL
|
| Solution | Intravenous |
300.000 mg
|
| Injection, solution, concentrate | — |
300 mg/10ml
|
| Injection, solution, concentrate | Intravenous |
300 mg/10mL
|
| Injection, solution | Subcutaneous |
|
| Solution, concentrate | Intravenous |
3000000 mg
|